Business
Medicus Pharma Reports First Quarter 2026 Financial Results and Provides Corporate Update
Company Advances SkinJect® and Teverelix® Clinical Programs While Strengthening Financing Flexibility and Expanding Strategic Development InitiativesPHILADELPHIA, May 14, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company"), a biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutics assets, today reported financial results for the three months ended March 31, 2026, and provided a corp
About this update from Medicus Pharma Ltd.
[{"type":"image","alt":"Medicus Pharma Ltd","displaySize":"","headline":null,"caption":"Medicus Pharma Ltd","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":105,"url":"https://media.zenfs.com/en/globenewswire.com/536b378d21fd9e670e64143c1efe36b1"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/uoifKLnfqp3oBT8AqCcLTg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE0Nw--/https://media.zenfs.com/en/globenewswire.com/536b378d21fd9e670e64143c1efe36b1","width":300,"height":105},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/uoifKLnfqp3oBT8AqCcLTg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE0Nw--/https://media.zenfs.com/en/globenewswire.com/536b378d21fd9e670e64143c1efe36b1","width":300,"height":105}},"lazy":false},{"type":"text","content":"Company Advances SkinJect® and Teverelix® Clinical Programs While Strengthening Financing Flexibility and Expanding Strategic Development Initiatives","length":149,"tagName":"p"},{"type":"text","content":"PHILADELPHIA, May 14, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company"), a biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutics assets, today reported financial results for the three months ended March 31, 2026, and provided a corporate update highlighting continued execution across its SkinJect® and Teverelix® development programs.","length":474,"tagName":"p"},{"type":"text","content":"During the first quarter of 2026, Medicus continued to advance its transition into a diversified clinical-stage biotechnology company with active development programs in dermatologic oncology and urology/oncology, while replenishing its balance sheet through multiple capital market initiatives.","length":295,"tagName":"p"},{"type":"text","content":"The Company recently reported positive, decision grade, expanded dataset findings from its Phase 2 SKNJCT-003 study evaluating SkinJect® Doxorubicin Microneedle Array (D-MNA) for the treatment of nodular basal cell carcinoma (BCC), including evidence of positive dose response and registrational grade clearance rates in the 200-µg treatment cohort.","length":349,"tagName":"p"},{"type":"text","content":"In parallel, Medicus advanced Teverelix®, its next-generation long-acting GnRH antagonist acquired through the acquisition of Antev Li...